Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878183 | 0.90 | MPO (0.42) | CAPN1MPOEGFRSRCTSHR | |
| Toluene SCHEMBL27339055 | 0.88 | CAPN1 (0.39) | CAPN1EGFRSRCTSHRRHEB | |
| SCHEMBL735832 | 0.82 | TSHR (0.53) | TSHRNAPRT | |
| Octadecanoic Acid Amide SCHEMBL28108802 | 0.80 | KDM4E (0.44) | KDM4E | |
| SCHEMBL10362176 | 0.80 | ALDH1A1 (0.48) | TSHRKDM4E | |
| SCHEMBL7813502 | 0.80 | TSHR (0.39) | TSHRNAPRTKDM4E | |
| SCHEMBL9978846 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL28879620 | 0.78 | GAA (0.38) | TSHRNAPRTKDM4E | |
| SCHEMBL11334170 | 0.77 | TSHR (0.37) | SRCTSHRNAPRTKDM4E | |
| Monoethanolamine SCHEMBL18979870 | 0.77 | TSHR (0.45) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-03-28 | — | — | US | disclosed |
| WO-2003045381-A1 | AMINOALKYLIMIDAZOLE DERIVATIVES AND THEIR USE IN MEDICINE | MOLECULAR SKINCARE LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
| EP-0569122-A1 | Pyrrole propionic acid amide, its production and use as calpain inhibitor | THE KITASATO INSTITUTE (JP) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | AURKC, AURKA, AURKB | CAPN1 3230/4885MPO 4883/4885EGFR 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.